Epstein Secrets

sued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or partic

erage universe. If it does not appear in the Ira runt Disclosures section of this report, the cettifying analyst's coverage universe can be found on M. Morgan's research website, Coverage Universe: Schott, Christopher: AbbVie (ABBV), Actavis plc (ACT), Allergan (AGN), Amarin Corporation (AMRN), Bristol-Mye

y-14 OW 57.11 64.00 4 EFTA00306886 Chris Schott. CFA North America Equity Research 1-21 622-5676 02 June 2014 J.P.Morgan The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire riot M. Morgan ratings or designations: OW -

sued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients' only. This material dos not take into account the specific investment objectives, financial situation or particu

OW 72.67 85.00 18-0ec-13 OW 73.59 100.00 EFTA00300342 Coon Ktorerom North America Equity Research 22 May 2014 J.RMorgan The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period. J.P. Morgan ratings or designations:

sued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients' only. JPMSAL does not issue or distribute this material to "retail clients". The recipient of this material must

), and Underwei ht (over the next three months, the recommended risk position is expected to underperform the relevant index, sector, or benchmark). M. Morgan's Emerging Market research uses a rating of Markenveight, which is equivalent to a Neutral rating. Valuation & Methodology: In M. Morgan's credit res

sued to persons regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or partic

4 OW 57.11 64.00 10-Oct-14 OW 59.21 66.00 20-Jan-15 OW 63.03 68.00 21-Sep-15 OW 52.13 65.00 30-Sep-15 OW 49.39 66.00 The chart(s) show M. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire M. Morgan ratings or designations: OW Overwei